CHICAGO — Data from two trials at the American College of Cardiology (ACC; Washington) 61st Annual Scientific Session and Expo, 2012 suggests that Medtronic's (Minneapolis) renal denervation system provides a significant benefit to patients suffering from treatment-resistant hypertension.